Pacific Biosciences of California (NASDAQ:PACB) Analyst Rating Consensus

Pacific Biosciences of California (NASDAQ:PACB) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.5 by 4 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. MKM Partners initiates coverage on Pacific Biosciences of California (NASDAQ:PACB) The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency announces the price target to $16.5 per share. The rating by the firm was issued on April 15, 2016.

Pacific Biosciences of California (NASDAQ:PACB): 4 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $12 in Pacific Biosciences of California (NASDAQ:PACB). However, the stock price could fluctuate by $ 4.24 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $18 price target with the lower price estimate is calculated at $8

Pacific Biosciences of California (NASDAQ:PACB) witnessed a decline in the market cap on Tuesday as its shares dropped 1.45% or 0.13 points. After the session commenced at $8.87, the stock reached the higher end at $8.9793 while it hit a low of $8.68. With the volume soaring to 916,543 shares, the last trade was called at $8.81. The company has a 52-week high of $14. The company has a market cap of $768 million and there are 87,168,677 shares in outstanding. The 52-week low of the share price is $3.58.

Pacific Biosciences of California, Inc. has lost 2.11% in the last five trading days and dropped 8.61% in the last 4 weeks. Pacific Biosciences of California, Inc. is up 9.31% in the last 3-month period. Year-to-Date the stock performance stands at -32.9%.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.